BioTuesdays

Tag - Maxim Group

Maxim ups Daré Biosciences PT to $4 from $3

Maxim Group raised its price target for Daré Bioscience (NASDAQ:DARE) to $4 from $3, citing FDA approval of XACIATO vaginal gel as a treatment for bacterial vaginosis (BV) and a commercial launch in 2022. The stock...

Maxim starts Genenta Science at buy; PT $21

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12. Genenta is developing cancer therapeutics using an autologous ex...

NeuroSense Therapeutics

Maxim starts NeuroSense at buy; PT $7

Maxim Group initiated coverage of NeuroSense Therapeutics (NASDAQ:NRSN) with a “buy” rating and price target of $7. The stock closed at $2.53 on Jan. 6. NeuroSense is a clinical-stage company developing therapies for...

Maxim starts Quoin Pharma at buy; PT $5

Maxim Group initiated coverage of Quoin Pharmaceuticals (NASDAQ:QNRX) with a “buy” rating and price target of $5. The stock closed at $1.74 on Jan.6. Quoin is a clinical-stage company developing therapies for rare...

ayala logo

Maxim starts Ayala at buy; PT $22

Maxim Group initiated coverage of Ayala Pharmaceuticals (NASDAQ:AYLA) with a “buy” rating and $22 price target. The stock closed at $9 on Dec. 17. Ayala is developing two gamma-secretase inhibitors – AL101 and...

Citius Logo

Maxim starts Citius Pharma at buy; PT $4

Maxim Group launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and $4 price target. The stock closed at $1.62 on Nov. 29. Citius is a late-stage company with two “de-risked” Phase 3 assets:...

Acurx Pharmaceuticals

Maxim starts Acurx Pharma at buy; PT $12

Maxim Group initiated coverage of Acurx Pharmaceuticals (NASDAQ:ACXP) with a “buy” rating and $12 price target. The stock closed at $4.89 on Nov. 26. Acurx is developing ibezapolstat, a member of an emerging new class...

Protagenic Therapeutics

Maxim starts Protagenic Therapeutics at buy; PT $4

Maxim Group initiated coverage of Protagenic Therapeutics (NASDAQ:PTIX) with a “buy” rating and price target of $4. The stock closed at $1.80 on Oct. 28. Protagenic is developing its lead asset, PT00114, for the...

Kazia Therapeutics New

Maxim starts Kazia Therapeutics at buy; PT $18

Maxim Group initiated coverage of Kazia Therapeutics (NASDAQ:KZIA) with a “buy” rating and $18 price target. The stock closed at $10.71 on Oct. 13. Kazia is developing two oncology drug candidates: paxalisib, for brain...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.